Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
| Authors | Yvette Drew, Jonathan Ledermann, Geoff Hall, Daniel Rea, Ros Glasspool, Martin Highley, Gordon Jayson, Julieann Sludden, James Murray, David Jamieson, Sarah Halford, Gary Acton, Zoe Backholer, Raffaella Mangano, Alan Boddy, Nicola Curtin, Ruth Plummer |
| Journal | British journal of cancer
(Br J Cancer)
Vol. 114
Issue 12
Pg. e21
(06 14 2016)
ISSN: 1532-1827 [Electronic] England |
| PMID | 27228289
(Publication Type: Journal Article, Published Erratum)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|
